Glenmark Pharmaceuticals Ltd is in focus after multiple reports confirmed that the company has entered into a licensing agreement with U.S.-based Astria Therapeutics for the development of monoclonal antibodies. The collaboration is aimed at strengthening Glenmark’s research pipeline and expanding its biologics footprint.
In a related development, Astria Therapeutics announced positive initial results from its Phase 1a trial of STAR-0310, a monoclonal antibody candidate, according to CNBC-TV18. Early trial outcomes suggest the therapy has met safety and efficacy benchmarks, paving the way for further clinical development.
The dual updates highlight Glenmark’s strategic push into innovative therapies while partnering with global biotech players to advance novel biologic solutions. Investors are closely tracking the news as the partnership and trial progress could unlock significant long-term value in Glenmark’s specialty pipeline.
